OHI Stock Analysis: Omega Healthcare Investors | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 15.019m USD | 12M Return: 44.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 115M
EPS Trend: 90.4%
Qual. Beats: 0
Rev. Trend: 98.9%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Omega Healthcare Investors (NYSE: OHI) is a self-managed Real Estate Investment Trust (REIT) that provides financing and capital to the long-term healthcare sector, primarily through triple-net lease structures with third-party operators. The companys portfolio is concentrated in skilled nursing and assisted living facilities, including UK care homes, spanning 1,024 operating facilities across 42 U.S. states, the District of Columbia, and the UK/Jersey, leased to 88 different operators as of September 30, 2025. As a REIT, Omega is required to distribute at least 90% of its taxable income to shareholders, which generally results in a dividend-oriented investment profile. The company is headquartered in Hunt Valley, Maryland, has been publicly traded since 1992, and falls within the GICS Health Care REITs sub-industry.
- Skilled nursing occupancy recovery lifts operator rent coverage and cash flows
- Federal Reserve rate cuts compress dividend yield spread versus Treasuries
- Medicaid reimbursement rate increases support skilled nursing operator profitability
| Net Income: 632.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.34 > 1.0 |
| NWC/Revenue: 125.9% < 20% (prev 192.6%; Δ -66.68% < -1%) |
| CFO/TA 0.09 > 3% & CFO 915.5m > Net Income 632.1m |
| Net Debt (4.42b) to EBITDA (1.21b): 3.63 < 3 |
| Current Ratio: 3.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (315.1m) vs 12m ago 6.85% < -2% |
| Gross Margin: 85.02% > 18% (prev 98.70%; Δ -13.69% > 0.5%) |
| Asset Turnover: 12.43% > 50% (prev 11.18%; Δ 1.25% > 0%) |
| Interest Coverage Ratio: 4.16 > 6 (EBIT TTM 885.2m / Interest Expense TTM 212.6m) |
| A: 0.15 (Total Current Assets 2.32b - Total Current Liabilities 763.2m) / Total Assets 10.2b |
| B: -0.36 (Retained Earnings -3.67b / Total Assets 10.2b) |
| C: 0.09 (EBIT TTM 885.2m / Avg Total Assets 9.97b) |
| D: 1.09 (Book Value of Equity 5.19b / Total Liabilities 4.78b) |
| Altman-Z'' = 1.57 = BB |
| DSRI: 0.89 (Receivables 2.04b/2.01b, Revenue 1.24b/1.08b) |
| GMI: 1.16 (GM 98.70% / 85.02%) |
| AQI: 1.20 (AQ_t 0.12 / AQ_t-1 0.10) |
| SGI: 1.14 (Revenue 1.24b / 1.08b) |
| TATA: -0.03 (NI 632.1m - CFO 915.5m) / TA 10.2b) |
| Beneish M = -2.76 (Cap -4..+1) = A |
As of July 03, 2026, the stock is trading at USD 49.40 with a total of 1,626,615 shares traded. Over the past week, the price has changed by +3.74%, over one month by +10.24%, over three months by +11.37% and over the past year by +44.08%.
Current recommended Stop Loss: 47.80 (which is 3.2% or 1.6 ATR below the current price).
Omega Healthcare Investors has received a consensus analysts rating of 3.69. Therefore, it is recommended to hold OHI.
- StrongBuy: 4
- Buy: 3
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 50.7 | 2.5% |
P/E Trailing = 23.2705
P/E Forward = 10.1317
P/S = 12.2146
P/B = 2.7351
P/EG = 11.994
Revenue TTM = 1.24b USD
EBIT TTM = 885.2m USD
EBITDA TTM = 1.21b USD
Long Term Debt = 4.02b USD (from longTermDebt, last quarter)
Short Term Debt = 425.0m USD (from shortTermDebt, last quarter)
Debt = 4.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.42b USD (calculated: Debt 4.44b - CCE 26.1m)
Enterprise Value = 19.4b USD (15.0b + Debt 4.44b - CCE 26.1m)
Interest Coverage Ratio = 4.16 (Ebit TTM 885.2m / Interest Expense TTM 212.6m)
EV/FCF = 21.43x (Enterprise Value 19.4b / FCF TTM 907.1m)
FCF Yield = 4.67% (FCF TTM 907.1m / Enterprise Value 19.4b)
FCF Margin = 73.22% (FCF TTM 907.1m / Revenue TTM 1.24b)
Net Margin = 51.02% (Net Income TTM 632.1m / Revenue TTM 1.24b)
Gross Margin = 85.02% ((Revenue TTM 1.24b - Cost of Revenue TTM 185.6m) / Revenue TTM)
Gross Margin QoQ = none% (prev 47.22%)
Tobins Q-Ratio = 1.90 (Enterprise Value 19.4b / Total Assets 10.2b)
Interest Expense / Debt = 4.79% (Interest Expense 212.6m / Debt 4.44b)
Taxrate = 2.42% (16.2m / 672.2m)
NOPAT = 863.8m (EBIT 885.2m * (1 - 2.42%))
Current Ratio = 3.04 (Total Current Assets 2.32b / Total Current Liabilities 763.2m)
Debt / Equity = 0.86 (Debt 4.44b / totalStockholderEquity, last quarter 5.19b)
Debt / EBITDA = 3.63 (Net Debt 4.42b / EBITDA 1.21b)
Debt / FCF = 4.87 (Net Debt 4.42b / FCF TTM 907.1m)
Total Stockholder Equity = 5.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.34% (Net Income 632.1m / Total Assets 10.2b)
RoE = 12.40% (Net Income TTM 632.1m / Total Stockholder Equity 5.10b)
RoCE = 9.71% (EBIT 885.2m / Capital Employed (Equity 5.10b + L.T.Debt 4.02b))
RoIC = 8.75% (NOPAT 863.8m / Invested Capital 9.87b)
WACC = 5.23% (E(15.0b)/V(19.5b) * Re(5.39%) + D(4.44b)/V(19.5b) * Rd(4.79%) * (1-Tc(0.02)))
Discount Rate = 5.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 9.57%
[DCF] Terminal Value 77.97% ; FCFF base≈836.3m ; Y1≈958.7m ; Y5≈1.41b
[DCF] Fair Price = 56.47 (EV 21.2b - Net Debt 4.42b = Equity 16.8b / Shares 297.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 90.37 | EPS CAGR: 16.48% | SUE: -0.15 | # QB: 0
Revenue Correlation: 98.91 | Revenue CAGR: 14.15% | SUE: 0.70 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.49 | Chg30d=+0.35% | Revisions=N/A | Analysts=3
EPS current Year (2026-12-31): EPS=1.98 | Chg30d=-1.52% | Revisions=+0% | GrowthEPS=-2.7% | GrowthRev=+11.4%
EPS next Year (2027-12-31): EPS=2.03 | Chg30d=-0.78% | Revisions=+0% | GrowthEPS=+2.8% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: +0%